Nastorazepide (also known as Netazepide or YF476) is an investigational gastrin receptor antagonist primarily studied for its potential in treating gastrointestinal disorders related to excessive stomach acid production. It inhibits the gastrin receptor, which plays a key role in acid secretion, making it a candidate for managing conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. This mechanism may help alleviate symptoms like heartburn, acid regurgitation, and stomach pain. Additionally, research explores its use in combination with other therapies for enhanced effects in severe cases and its potential role in managing certain gastric cancers, where gastrin promotes tumor cell growth. Currently, Nastorazepide remains in the experimental and research phase, requiring further studies to confirm efficacy, safety, and clinical applications. It is not yet approved for standard therapeutic use and is valuable for patients unresponsive to conventional treatments in clinical trials.